Migraine Characteristics, Comorbidities, Healthcare Resource Utilization, and Associated Costs of Early Users of Erenumab in the USA: A Retrospective Cohort Study Using Administrative Claims Data

被引:0
作者
David Chandler
Christine Szekely
Shivani Aggarwal
Lori Cyprien
Mark Bensink
机构
[1] Amgen Inc.,Global Health Economics
[2] Amgen Inc.,Center for Observational Research
来源
Pain and Therapy | 2021年 / 10卷
关键词
Cost; Erenumab; Healthcare resource utilization; Migraine; Persistence;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:1551 / 1566
页数:15
相关论文
共 57 条
[1]  
Lipton RB(2007)Migraine prevalence, disease burden, and the need for preventive therapy Neurology 68 343-349
[2]  
Bigal ME(2011)Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS) Cephalalgia 31 301-315
[3]  
Diamond M(2009)The burden of migraine in the United States: current and emerging perspectives on disease management and economic analysis Value Health 12 55-64
[4]  
Blumenfeld AM(2011)Quality of life impairment, disability and economic burden associated with chronic daily headache, focusing on chronic migraine with or without medication overuse: a systematic review Cephalalgia 31 837-850
[5]  
Varon SF(2013)ACP journal club. Review: approved and some off-label preventive drugs reduce migraine frequency in episodic migraine Ann Intern Med 159 JC11-33
[6]  
Wilcox TK(2015)A narrative review of evidence-based preventive options for chronic migraine Curr Pain Headache Rep 19 49-488
[7]  
Hazard E(2014)Systematic review of migraine prophylaxis adherence and persistence J Manag Care Pharm 20 22-485
[8]  
Munakata J(2015)Adherence to oral migraine-preventive medications among patients with chronic migraine Cephalalgia 35 478-1343
[9]  
Bigal ME(2017)Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis Cephalalgia 37 470-19
[10]  
Lanteri-Minet M(2020)Burden of illness among people with migraine and >/= 4 monthly headache days while using acute and/or preventive prescription medications for migraine J Manag Care Spec Pharm 26 1334-126